The "Pharmaceutical Sciences" section presented diverse, interdisciplinary research addressing complex healthcare challenges, including drug formulation, preclinical and clinical studies, adverse effects, in vitro disease modelling, and gene polymorphisms.Contributions from Latvia, Lithuania, and India highlighted strong international collaboration.In the domain of preclinical drug studies, the abstracts provided insights in vitro models of NAFLD and Parkinsons disease.Findings supported the hepatoprotective potential of anti-diabetic drugs and highlighted their promise as therapeutic agents in NAFLD.The studies on anti-Parkinsonian effects of selected polyphenols in in vitro PD models were focused on DA metabolism and Syn aggregation.The obtained data indicated that polyphenols function as multifunctional agents targeting key neurodegenerative processes in PD by inhibiting MAO-B activity and suppressing toxic Syn aggregation.Further research is needed on 20S proteasome modulation in neuroprotection.Research on Silybum marianum examined phenolic metabolites and key enzymes involved in biosynthesis across growth stages, providing insight into plant biochemical composition.Addressing antimicrobial resistance, 74 bacterial strains were isolated from Latvian wooded dunes, including 23 Streptomyces strains.Several extracts showed activity against Gram-positive pathogens such as Staphylococcus aureus and Bacillus subtilis, identifying promising natural product candidates for novel antimicrobial compounds.A retrospective study (2019-2025) of psoriasis patients treated with biological therapies (adalimumab, ustekinumab, secukinumab or risankizumab) confirmed improved disease control but highlighted the need to further evaluate laboratory-defined adverse effects, such as liver enzyme elevation and neutropenia.In multiple sclerosis research, proteasome gene polymorphisms and vitamin D pathway genetics showed therapy-specific associations with "no evidence of disease activity" (NEDA), supporting gene-treatment interaction and personalised therapy approaches.Advances in drug formulation include stabilisation of amorphous empagliflozin using electrospun nanofibres, offering a sustainable method to improve drug solubility.Cocrystallisation studies identified new crystalline phases, aiding solid-form optimisation of active pharmaceutical ingredients.Innovations in drug delivery show that semi-solid extrusion 3D printing enhances transdermal menthol delivery compared to conventional methods, while also influencing key quality attributes of pharmaceutical films.Finally, research on haemostatic materials demonstrated that Prussian blue-clay composites affect coagulation behaviour, indicating potential applications in contaminated environments.Overall, this section highlights the integration of pharmaceutical manufacturing, biomedical research, and clinical studies, emphasising the development of innovative drugs and delivery systems for improved healthcare outcomes.
Muceniece et al. (Wed,) studied this question.